Immunomagnetic cell separation in the IsoFlux System is based on the binding of magnetic particles to surface antigens that are present in CTCs but absent in surrounding leukocytes. The types and numbers of target cells recovered with the IsoFlux System will depend on the capture markers used. Certain markers, such as EpCAM, are generally understood to be present in most carcinomas (cancers of epithelial origin), but the expression of single markers can be heterogeneous in CTCs.
Given the heterogeneity of the CTC population and likely variations between different cancer types, it is advantageous to be able to separate CTCs based on multiple surface markers. The ability to select the surface marker of interest can also aid in selecting specific CTC sub-populations.
In addition to CTCs, many other rare cell types of scientific and clinical interest can exist in the peripheral blood circulation. These include cancer stem cells, immune cells, and circulating endothelial cells. In many cases, these cells can also be enriched from the background cells using one or more surface-expressed antigens.
For more detailed information, download a representative protocol:
This document is intended to guide the user through a method for using multiple antibody types conjugated to magnetic beads to recover circulating tumor cells (CTCs). This protocol provides specific instructions for the use of EpCAM, EGFR, and HER-2 antibodies, and guidelines for protocol optimization if other surface markers are to be used. The protocol incorporates use of the IsoFlux System and the IsoFlux Rare Cell Enrichment Kit.